Dalton, Greiner, Hartman, Maher & Co’s Harvard Bioscience HBIO Stock Holding History

Dalton, Greiner, Hartman, Maher & Co’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,947	Closed	-$489K	–	58
2021 Q1	$489K	Sell	8,947 -14,964	-63%	-$728K	0.39%	111
2020 Q4	$1.03M	Sell	23,911 -67,087	-74%	-$2.5M	0.22%	102
2020 Q3	$2.74M	Sell	90,998 -74,916	-45%	-$2.52M	0.45%	76
2020 Q2	$5.14M	Buy	165,914 +3,975	+2%	+$107K	0.51%	76
2020 Q1	$3.58M	Buy	161,939 +4,541	+3%	+$123K	0.37%	108
2019 Q4	$4.8M	Buy	157,398 +20,046	+15%	+$577K	0.33%	121
2019 Q3	$4.22M	Buy	137,352 +21,814	+19%	+$542K	0.29%	124
2019 Q2	$2.31M	Buy	115,538 +106,701	+1,207%	+$3.13M	0.19%	125
2019 Q1	$381K	Buy	+8,837	New	+$320K	0.03%	158

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dalton, Greiner, Hartman, Maher & Co's HBIO Position: Q2 2021 in Review

Dalton, Greiner, Hartman, Maher & Co sold out of Harvard Bioscience (HBIO) in Q2 2021, closing a stake of 8,947 shares — an estimated $489K sold.

Dalton, Greiner, Hartman, Maher & Co first reported a position in HBIO in Q1 2019 and held it in 9 quarters. The position peaked at $5.14M in Q2 2020. 99 funds tracked by Wall St. Rank hold HBIO as of Q2 2021.

Dalton, Greiner, Hartman, Maher & Co reported no remaining Harvard Bioscience position as of Q2 2021 after selling out during the quarter.
Dalton, Greiner, Hartman, Maher & Co sold 8,947 Harvard Bioscience shares in Q2 2021, an estimated $489K.
Dalton, Greiner, Hartman, Maher & Co first reported a position in Harvard Bioscience in Q1 2019 and held it in 9 quarters.
Dalton, Greiner, Hartman, Maher & Co's Harvard Bioscience position peaked at $5.14M in Q2 2020.
99 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2021.

Based on Dalton, Greiner, Hartman, Maher & Co's 13F filing for Q2 2021.